ABOS Acumen Pharmaceuticals, Inc.

NASDAQ
$0.21

Acumen Pharmaceuticals, Inc. (ABOS) is expected to report earnings on January 25, 2027, before the market open. The consensus earnings estimate is a loss of $0.32 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -90.1% since its last earnings release on October 26, 2026.

Acumen Pharmaceuticals Beat Consensus Estimates
Monday, October 26, 2026 · 7:00 AM ET
Earnings Date
4th Quarter, Dec 2026
Jan 25
Monday · 7:00 AM ET
Earnings Whisper
-
vs ($0.32)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $0.37

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Acumen Pharmaceuticals, Inc.

Acumen is a clinical stage biopharmaceutical company developing a novel disease-modifying approach to treat Alzheimer’s disease.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.